Community protocols on TRT describe: CJC-1295 (no DAC): 100 mcg subcutaneous, 2-3x daily (pre-bed dose described as most important) CJC-1295 (with DAC): 2 mg subcutaneous, 1-2x per week Starting after the TRT protocol is stable (8+ weeks) Monitoring IGF-1 at the 4-week and 12-week marks For reconstitution and detailed protocols, see our CJC-1295 dosing guide and CJC-1295 DAC dosing guide
Systematic review of progressive familial intrahepatic cholestasis
A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks
MMP and TIMP modulation: GHK-Cu regulates both matrix metalloproteinases and their inhibitors, favoring organized matrix remodeling
The follow-up period varied widely between 6 and 12 months after injection making it hard to know when and how recovery occurred
A qualified medical provider can help you: Determine if medication is appropriate for your health profile Explain realistic expectations and outcomes Identify risks, side effects, and long-term considerations Build a plan that may include medical weight loss, lifestyle changes, or surgical options if needed For many patients, this is the first step toward a structured, physician-guided approach instead of trial-and-error dieting
